Operating Expenses
Acquired IPR&D Expense
Eli Lilly Acquired IPR&D Expense increased by 10.4% to $584.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 62.8%, from $1.57B to $584.00M. Over 3 years (FY 2021 to FY 2025), Acquired IPR&D Expense shows an upward trend with a 44.2% CAGR.
Analysis
StatementIncome Statement
SectionOperating Expenses
First reportedQ1 2021
Last reportedQ1 2026Apr 30, 2026
Metric ID:
abbv_acquired_iprd_expenseHistorical Data
18 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $242.53M | $242.53M | $242.53M | $62.40M | $240.10M | $105.00M | $97.10M | $2.98B | $622.80M | $110.50M | $154.30M | $2.83B | $188.80M | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
| QoQ Change | — | +0.0% | +0.0% | -74.3% | +284.8% | -56.3% | -7.5% | >999% | -79.1% | -82.3% | +39.6% | >999% | -93.3% | +732.6% | -90.2% | +326.3% | -19.4% | +10.4% |
| YoY Change | — | — | — | -74.3% | -1.0% | — | — | >999% | +159.4% | +5.2% | +58.9% | -5.0% | -69.7% | >999% | -0.3% | -76.8% | +180.1% | -62.8% |
Range$62.40M – $2.98B
CAGR+23.0%
Avg YoY Growth+469.5%
Median YoY Growth-0.3%
Business Segments
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| Reportable Segment | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
| Total | $1.57B | $153.80M | $655.70M | $528.80M | $584.00M |
Acquired IPR&D Expense at Other Companies
Frequently Asked Questions
- What is Eli Lilly's acquired ipr&d expense?
- Eli Lilly (LLY) reported acquired ipr&d expense of $584.00M in Q1 2026.
- How has Eli Lilly's acquired ipr&d expense changed year-over-year?
- Eli Lilly's acquired ipr&d expense decreased by 62.8% year-over-year, from $1.57B to $584.00M.
- What is the long-term trend for Eli Lilly's acquired ipr&d expense?
- Over 3 years (2021 to 2025), Eli Lilly's acquired ipr&d expense has grown at a 44.2% compound annual growth rate (CAGR), from $970.10M to $2.91B.